Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5954)	3/19/2002 4:17:40 PM
From: Ian@SI	Respond to of 52153

Somebody owns each share. And I doubt that anyone will feel a need to own more shares any time soon. i.e. - Short covering is unlikely to act as a floor short term. While I agree that the committee recommendation won't shock many, if any, VPHM holders, we'll see downside when it opens though probably not as much as when MRVT announced that their lead drug didn't show any efficacy. In any case, it's too late to modify any positions. Best wishes, Ian

To: Biomaven who wrote (5954)	3/19/2002 5:56:00 PM
From: Vector1	Respond to of 52153

Biomaven, it will be interesting to see of the advisory committee provides any guidance as to what would satisfy them from a safety standpoint. Converts might be an interesting play. V1

To: Biomaven who wrote (5954)	3/19/2002 6:04:01 PM
From: smh	Respond to of 52153

Abuse of BT patent rights? -------------------------------------------- Patent owners stall fast HIV test Long wait for results cuts effectiveness in fighting disease By Geeta Anand THE WALL STREET JOURNAL msnbc.com ...The Centers for Disease Control and Prevention and U.S. Army officials say an easy-to-use, rapid HIV test is vital to reducing the U.S. rate of HIV transmission — which remains stubbornly high at 40,000 new cases a year and is rising sharply in low-income, minority populations. According to CDC estimates, each year one-third of the 2.1 million people tested for HIV at public clinics don’t come back for their results. Many go on unwittingly to infect others. At the public clinic Norris visited, 200 of the 500 people tested during the past two years didn’t pick up their results, the clinic says. Many of these people are poor and transient, making it hard for the clinic to track them down. But simple, fast HIV tests, which are commonly used in dozens of other countries, aren’t available in the U.S. The reason: a patent granted over a decade ago on a rare form of the virus. The company that controls the patent, the big diagnostic-products maker Bio-Rad Laboratories Inc., has been approached by several small companies seeking licensing rights to sell their fast HIV tests here. Bio-Rad refused. Bio-Rad did sell some licensing rights to three big companies, but those companies don’t sell easy-to-use tests in the U.S. Critics at the CDC and the military say Bio-Rad and its three big U.S. licensees — Abbott Laboratories Inc., Chiron Corp. and Johnson & Johnson — have little incentive to sell a rapid test domestically because they already dominate the $200 million U.S. market for the slower, lab-based HIV tests. Abbott, in particular, is the biggest U.S. seller of the slower tests. Quick tests would require the companies to conduct expensive clinical trials, and would likely siphon off sales of slower tests, the critics say. <snip>